Xenon Pharmaceuticals (XENE) Scheduled to Post Quarterly Earnings on Tuesday

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Xenon Pharmaceuticals to post earnings of ($0.82) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same period in the prior year, the company earned ($0.72) EPS. On average, analysts expect Xenon Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE traded up $1.61 during trading hours on Wednesday, hitting $44.94. The stock had a trading volume of 347,744 shares, compared to its average volume of 385,884. The company has a 50 day simple moving average of $40.67 and a two-hundred day simple moving average of $40.19. Xenon Pharmaceuticals has a one year low of $27.99 and a one year high of $50.99. The firm has a market capitalization of $3.40 billion, a price-to-earnings ratio of -15.81 and a beta of 1.25.

Analyst Ratings Changes

Several brokerages have commented on XENE. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. HC Wainwright began coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, October 1st. They issued a "buy" rating and a $53.00 price target for the company. Needham & Company LLC cut their price target on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a "buy" rating for the company in a report on Monday, August 12th. Raymond James restated an "outperform" rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $57.45.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.